Comprehensive Genomic Profiling is one of six urgent lung cancer reforms needed
Six key reforms are needed to address systemic gaps in lung cancer diagnosis and treatment in Australia, according to a new report from the Lung Foundation. As well as implementing the recommended national lung cancer screening program, there is also a need for government-funded Comprehensive Genomic Profiling as standard of...
Are Australian oncologists too cosy with industry?
Over three quarters of Australian cancer specialists interact with a drug company rep at least monthly and two thirds have received some form of pharma funding in their career, researchers have found. But only a minority believe there is anything problematic in the relationship between the medical oncology and haematology specialties...
PBS costs blow out for protein kinase inhibitors
A PBS review of locally advanced and metastatic breast cancer treatments has found that uptake of palbociclib has been far higher than predicted and the drug is already costing taxpayers more than any other breast cancer medication. The cost blowout comes in spite of the drug still being prescribed to less...
Aussie research reveals collagen’s role in breast cancer metastasis
Collagen XII might have a role as a predictor of metastasis risk in patients with breast cancer including triple negative breast cancer, Australian researchers say. Research from the Garvan Institute has highlighted the role of collagen XII in creating a “pro-invasive...
Collagen XII might have a role as a predictor of metastasis risk in patients with breast cancer including triple negative...
Adjuvant immunotherapy in early-stage NSCLC: ‘watch this space’
Eagerly-awaited overall survival findings for adjuvant atezolizumab immunotherapy in patients with non-small cell lung cancer (NSCLC) suggest the benefit may be confined to people with high levels of tumour PD-L1 expression. The significant benefits previously seen in disease-free survival with atezolizumab...
Eagerly-awaited overall survival findings for adjuvant atezolizumab immunotherapy in patients with non-small cell lung cancer (NSCLC) suggest the benefit may...
6 Optimal Care Pathways launched for blood cancers
Six new Optimal Care Pathways for blood cancers have been developed with the aim of setting consistent standards of care that should be available to all patients treated in Australia. The pathways covering conditions such as leukaemia, lymphoma and myeloma...
Six new Optimal Care Pathways for blood cancers have been developed with the aim of setting consistent standards of care...